GlassScriptPhysician profile
Doron Amir
NPI 1366440026
$20,711.09
in general payments reported to CMS, 2019-2025
58 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,387 · 2020: $1,161 · 2021: $1,604 · 2022: $3,280 · 2023: $3,376 · 2024: $4,364 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $30.32 · Consulting Fee: $17.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,232.27 |
| Education | $30.32 |
| Consulting Fee | $17.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,853.64 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Janssen Pharmaceuticals, INC | $1,625.93 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,520.15 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,510.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,474.04 | 2019-2025 | Farxiga, Wainua, Fasenra |
| Pfizer INC. | $1,401.32 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,354.13 | 2019-2025 | |
| Abbvie INC. | $984.10 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $962.92 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $920.78 | 2021-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $843.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $814.31 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $642.40 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $605.10 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $334.35 | 2020-2025 | Amvuttra, Onpattro |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $299.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $288.70 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $274.45 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $248.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $238.30 | 2019-2022 | |
| Bridgebio Pharma, INC. | $227.26 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $226.31 | 2019 | |
| Inspire Medical Systems, INC. | $161.84 | 2024-2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $145.97 | 2022-2024 | Linzess |
| Kowa Pharmaceuticals America, INC. | $130.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.09 | 2023-2025 | Xifaxan |
| Redhill Biopharma INC. | $123.98 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $108.54 | 2023-2024 | Ztlido |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.33 | 2019-2024 | Lifevest |
| Heartflow, INC. | $88.48 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $76.56 | 2022 | |
| Irhythm Technologies, INC. | $74.92 | 2022 | |
| Cvrx, INC. | $72.65 | 2023 | Barostim Neo System |
| Agepha Pharma Fz LLC | $71.59 | 2024 | Lodoco |
| Lundbeck LLC | $56.23 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.34 | 2025 | Caplyta |
| Atricure, INC. | $52.60 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals International, Plc | $51.21 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $45.94 | 2023-2024 | Inpefa |
| Medicomp INC | $45.90 | 2024 | Telepatch Cardiac Monitor |
| Currax Pharmaceuticals LLC | $44.46 | 2023-2025 | Contrave, Nexlizet, Nexletol |
| Medtronic, INC. | $41.40 | 2024 | Corevalve Evolut R |
| Idorsia Pharmaceuticals US INC | $41.31 | 2024 | Quviviq |
| Intra-Sana Laboratories | $37.79 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Bardy Diagnostics, INC. | $37.28 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $33.81 | 2023 | Arcalyst |
| Optos, INC. | $26.83 | 2020 | |
| Dexcom, INC. | $26.68 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $25.00 | 2025 | Gvoke Hypopen |
| Viatris Specialty LLC | $23.65 | 2025 | Yupelri |
| Viiv Healthcare Company | $21.88 | 2023 | Apretude |
| Altathera Pharmaceuticals LLC | $20.85 | 2025 | Sotalol Hydrochloride |
| Baxter Healthcare | $17.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Phadia US INC. | $15.94 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $15.42 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $15.05 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $11.56 | 2025 | Rhythm Express |
| Gilead Sciences, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doron Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.